配体靶向纳米药物抗肿瘤的研究进展

The Research Progress of Ligand-targeted Particulate Nanomedicines against Tumor

目前,已有13种靶向配体纳米微粒(PNMs)进入临床试验阶段,包括基于脂质体和基于聚合物以及逆转录病毒载体和细菌衍生型细胞等运载形式。本文主要从以下方面分别对此13种靶向配体纳米药物的研究进展进行综述:(1)配体靶向PNMs的前期临床试验;(2)配体靶向PNMs在恶性肿瘤治疗中的应用;(3)靶向配体对于靶向PNMs药物所起的作用;(4)PNMs作用于靶组织中的位置不会受到相关靶向配体的影响,有利于定位于靶细胞,提升其特异性。并就其靶向配体PNMs未来的发展方向进行展望。

There are 13 kinds of ligand-targeted particulate nanomedicines（PNMs） which have stepped into clinical trials so far, including delivery forms based on liposomes, polymers, retrovirus vectors and bacteria-derived cells and so on. This review emphasized the research progress about 13 kinds of ligand-targeted PNMs. Main contents included：（1） the preliminary clinical trials of ligand-targeted PNMs;（2） the application of ligand-targeted PNMs in malignant tumor;（3） the role of ligands in PNMs;（4） the acting positions of ligand-targeted PNMs in target tissue are not subject to ligands. This advantage will help for location, and then improve their specificity. In the end, we talked about the prospect development of ligand-targeted PNMs.